Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Doorbraak in behandeling van maag- en slokdarmkanker
jan 2024 | Immuuntherapie, Maag-darm-leveroncologie